This trader lost a lot of money by shorting KaloBios Pharmaceuticals Inc, which went up on the news that Martin Shkreli had taken an ownership stake in them. Y

This trader lost a lot of money by shorting KaloBios Pharmaceuticals Inc, which went up on the news that Martin Shkreli had taken an ownership stake in them. You may remember Martin Shkreli having been in the news recently for a different reason: he's the hedge fund manager who bought the exclusive right to manufacture Daraprim, and raised its price from $13.50/tablet to $750/tablet, to much outrage. (Daraprim is not subject to patent, but only one manufacturer is allowed to sell it in the United States due to the combination of a small market and regulatory dysfunction at the FDA.)